Audit: QRS - Sulforaphane for Health & Longevity

Audit conducted on 11/01/2026 18:03 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	97
Passed	88
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, protocol, time-to-effect, tiers, gates, monitoring and qualitative items all trace to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Benefits/Risks headings, Key Interactions, Monitoring table)
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Lede keeps “modest and less certain”, “at most a slight”, “unproven”; theoretical interactions keep “could”
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found; contraindications keep “outside a trial”, theoretical items keep conditional phrasing
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from “Populations who should avoid”; no modifying factor relabeled
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT IDs or brand names (Avmacol, Kagome) appear

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is expert, accessible, objective, and data-driven	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses the reader directly — it presents evidence, not guidance	🟢	No second-person address
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms (CYP1A2, UGT1A1, Nrf2, myrosinase, glucoraphanin) sit in or derive from ER labels carried verbatim
2.8	Information is presented in a concise and very compact manner	🟢
2.9	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.10	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.11	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede notes the autism signal does not bear on healthy aging and frames adult findings separately
2.13	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Lede uses “longevity”; no “anti-aging”
2.14	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial route or event terms; “Gastrointestinal adverse events” used

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers unchanged (lines 446, 483, 525, 545, 558, 590, 609, 613-615, 728)
3.2	Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name	🟢	All template variables present; marker_# and qualitative_item_# expanded to numbered names per 14.2/15.2
3.3	Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well	🟢	Diff against template shows changes only inside data-qrs-var spans, the metadata block, and the display:none on risks_medium required by 13.5

4. Formatting

#	Description	Result	Comments
4.1	An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over.	🟢	Empty Medium risk tier hidden (line 595); no empty-state text
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol, contraindication, interaction and qualitative labels use ER bold labels
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Interaction labels only drop example names or in-label glosses (e.g., glipizide, tizanidine, “stomach-acid reducers”)
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators
4.5	The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit.	🟢	No trailing dash clauses, optional glosses, untrimmed example lists or repetitions found

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment directly follows <!doctype html> (lines 2-14)
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Inside an HTML comment
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; duration quoted because it contains a colon
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: sulforaphane_2026-1101-1211_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.10.25 matches QRS.md
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-1101-1735
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.5
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename matches the file name

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Sulforaphane for Health & Longevity - Quick Reference Sheet” (line 21)
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 423
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	11/01/2026 from qrs_creation_date 2026-1101-1735
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with “a broccoli-derived supplement marketed for longevity”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER “Populations who should avoid” items present (lines 548-553)
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Labels only; inferential rationale stripped
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“outside a trial”, “with iodine deficiency” kept
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation in the ER items
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated; ER names six populations
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found	🟢	Four documented interactions; CYP3A4 and antipsychotic “No interaction found” entries excluded
9.3	[caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label	🟢	All six ER theoretical interactions present
9.4	The ER placeholder “None identified” is never an item: it means that group is empty	🟢
9.5	Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause	🟢	No “(theoretical)”, “inferred from” or mechanism clauses in items
9.6	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Recommendation tails (“so dosing is reviewed”, “so oncologists are informed”) stripped
9.7	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Each label keeps at least one ER example
9.8	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation in the ER items
9.9	If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER theoretical group is not empty
9.10	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated; ER lists documented and theoretical interactions
9.11	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g.	N/A	Section is not empty

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Therapeutic Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from that section	🟢	Extract, stabilized sulforaphane and whole-sprout approaches with trial doses
10.3	If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER provides three or more actionable aspects
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	From ER Practical Considerations “Time to effect” bullet
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Behavioral/depression (High/Medium benefits), PSA (Low), detoxification markers (Speculative)
11.3	If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER provides three time-to-effect aspects
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER provides time-to-effect information

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are ER headings without magnitudes or qualifiers
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals
12.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	Every benefit tier has items

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are ER headings without frequencies
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals
13.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Empty Medium tier hidden with style=”display:none” (line 595)

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
14.2	All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names	🟢	Seven ER table markers plus γ-GTP and peak flow named in the section text; rows numbered 1-9
14.3	[marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER”	🟢	Targets from ER table; γ-GTP and peak flow written “Not specified in the ER”
14.4	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty.	🟢	Line 722
14.5	If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template	N/A	ER names measurable biomarkers

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
15.2	All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 …	🟢	All five ER qualitative markers present, numbered 1-5
15.3	If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template	N/A	ER names qualitative markers

Issues 11/01/2026 18:03

Pass rate 100.00%. No issues found.

Issues 11/01/2026 18:00

1. 14.3 — γ-GTP purpose missing: marker_5_why at line 671 reads “Liver enzyme; paired with ALT”, describing the marker instead of stating why it is measured (the ER lists liver enzymes as markers expected to change, falling in fatty liver).

Fixes 11/01/2026 18:00

1. 14.3 — γ-GTP purpose stated: Changed marker_5_why from “Liver enzyme; paired with ALT” to “May fall in fatty liver; paired with ALT”.

Issues 11/01/2026 17:54

1. 7.5 — Research jargon in lede: The at_a_glance text at line 439 uses “signal” twice (“Its most consistent signal”, “a cholesterol-lowering signal”), an evidence-appraisal term rather than plain language.
2. 14.1 — Marker purpose from elsewhere: marker_5_why at line 671 adds “lower baseline linked to larger glucose response”, a benefit-modifying factor from ER lines 235/366, not content of the Monitoring section (ER line 415 says only “pair with γ-GTP”).

Fixes 11/01/2026 17:54

1. 7.5 — Research jargon in lede: Replaced “Its most consistent signal” with “Its most consistent result” and “a cholesterol-lowering signal” with “possible cholesterol lowering”; the lede stays at 70 words.
2. 14.1 — Marker purpose from elsewhere: Changed marker_5_why from “Paired with ALT; lower baseline linked to larger glucose response” to “Liver enzyme; paired with ALT”, following the Monitoring section (ER lines 406, 415).

Issues 11/01/2026 17:52

1. 1.2 / 1.3 — Expected effect stated as fact: The Myrosinase sources interaction at line 563 reads “stronger effects, including gastrointestinal ones”, dropping the ER’s hedge “are expected” (ER line 315) and turning a predicted consequence into a stated one.
2. 4.5 — Repeated drug name: The UGT1A1 substrates item at line 576 reads “(irinotecan): irinotecan exposure could fall”, repeating the label’s example in the consequence.

Fixes 11/01/2026 17:52

1. 1.2 / 1.3 — Expected effect stated as fact: Restored the ER hedge on the Myrosinase sources item: “stronger effects, including gastrointestinal ones” → “stronger effects, including gastrointestinal ones, are expected”.
2. 4.5 — Repeated drug name: Removed the repeated drug name from the UGT1A1 substrates item: “irinotecan exposure could fall” → “exposure could fall”.

Issues 11/01/2026 17:48

1. 1.1 / 7.4 — Marketing label as fact: The At-A-Glance at line 439 calls sulforaphane “a broccoli-derived longevity supplement”, while the ER says only that it is “marketed to health-focused adults as a daily longevity supplement” and that “its value for longevity remains unproven”.
2. 14.2 — Peak flow marker missing: The ER monitoring section has people with asthma “track symptoms and peak flow during the first 2 weeks”, but the Monitoring table (lines 619-706) has no peak flow row.

Fixes 11/01/2026 17:48

1. 1.1 / 7.4 — Marketing label as fact: Changed the lede opening from “a broccoli-derived longevity supplement, switches on” to “a broccoli-derived supplement marketed for longevity, activates”, and shortened “small gains in autism-related behavior” to “small autism-related behavioral gains” to keep the lede at 70 words.
2. 14.2 — Peak flow marker missing: Added Monitoring row marker_9: “Peak flow (people with asthma)” / “Not specified in the ER” / “Safety check; airway responsiveness may worsen”.

Issues 11/01/2026 17:45

1. 14.2 — γ-GTP marker missing: The Monitoring table (lines 619-695) lists seven markers but omits γ-GTP, which the ER Monitoring section names in the ALT row (“pair with γ-GTP”) as part of the liver-enzyme panel.

Fixes 11/01/2026 17:45

1. 14.2 — γ-GTP marker added: Added a γ-GTP row after ALT in the Monitoring table (target “Not specified in the ER”, why “Paired with ALT; lower baseline linked to larger glucose response”) and renumbered the following markers 6–8.

Issues 11/01/2026 17:41

1. 1.3 — Subgroup qualifier dropped: The At a Glance text (line 439) says “at most a slight blood sugar effect in early diabetes”, while the ER Conclusion limits it to “in some people with early diabetes”, broadening a subgroup finding.

Fixes 11/01/2026 17:41

1. 1.3 — Subgroup qualifier restored: Changed “in early diabetes” to “in some people with early diabetes” in the At a Glance text, and shortened “a broccoli-derived supplement taken for longevity” to “a broccoli-derived longevity supplement” to stay within 70 words.

Issues 11/01/2026 17:38

1. 1.1 / 14.3 — Target qualifier dropped: marker_7_target at line 690 reads “No established target; track change from own pre-supplement level”, omitting the ER’s “for this use” and so implying clozapine/theophylline levels have no established target at all.
2. 2.7 — Jargon in time cell: time_3_sub at line 517 “Higher urinary excretion of pollutant conjugates” uses the specialist term “conjugates” outside any ER label.
3. 7.2 — Dangling comparative in lede: Line 439 “For adults, findings are modest and less certain” drops the Conclusion’s comparator (the small autism-behavior signal), leaving “less certain” without a referent.

Fixes 11/01/2026 17:38

1. 1.1 / 14.3 — Target qualifier restored: Changed marker_7_target from “No established target; track change…” to “No established target for this use; track change from own pre-supplement level”, matching the ER.
2. 2.7 — Jargon replaced in time cell: Changed time_3_sub from “pollutant conjugates” to “pollutant breakdown products”.
3. 7.2 — Lede comparator restored: Rewrote the lede to name the most consistent signal (small gains in autism-related behavior, not bearing on healthy aging) before “Adult findings are modest and less certain”, keeping it at 69 words.